1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Leukodystrophies - Pipeline Review, H1 2015

Leukodystrophies - Pipeline Review, H1 2015

  • February 2015
  • -
  • Global Markets Direct
  • -
  • 41 pages

Leukodystrophies - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Leukodystrophies - Pipeline Review, H1 2015’, provides an overview of the Leukodystrophies’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Leukodystrophies, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Leukodystrophies and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Leukodystrophies
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Leukodystrophies and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Leukodystrophies products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Leukodystrophies pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Leukodystrophies
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Leukodystrophies pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Leukodystrophies - Pipeline Review, H1 2015
Table of Contents
Introduction 5
Global Markets Direct Report Coverage 5
Leukodystrophies Overview 6
Therapeutics Development 7
Pipeline Products for Leukodystrophies - Overview 7
Pipeline Products for Leukodystrophies - Comparative Analysis 8
Leukodystrophies - Therapeutics under Development by Companies 9
Leukodystrophies - Pipeline Products Glance 10
Clinical Stage Products 10
Early Stage Products 11
Leukodystrophies - Products under Development by Companies 12
Leukodystrophies - Companies Involved in Therapeutics Development 13
ArmaGen Technologies, Inc. 13
Fate Therapeutics, Inc. 14
GlaxoSmithKline plc 15
Phenomenome Discoveries, Inc. 16
ReGenX Biosciences, LLC 17
Shire Plc 18
Leukodystrophies - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 21
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Drug Profiles 26
AGT-183 - Drug Profile 26
Product Description 26
Mechanism of Action 26
RandD Progress 26
FT-1050 - Drug Profile 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
Gene Therapy to Activate Arylsulfatase A for Metachromatic Leukodystrophy - Drug Profile 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
GSK-2696274 - Drug Profile 32
Product Description 32
Mechanism of Action 32
RandD Progress 32
PPI-1011 - Drug Profile 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
SHP-611 - Drug Profile 34
Product Description 34
Mechanism of Action 34
RandD Progress 34
Leukodystrophies - Recent Pipeline Updates 35
Leukodystrophies - Dormant Projects 38
Leukodystrophies - Discontinued Products 39
Appendix 40
Methodology 40
Coverage 40
Secondary Research 40
Primary Research 40
Expert Panel Validation 40
Contact Us 40
Disclaimer 41

List of Tables

Number of Products under Development for Leukodystrophies, H1 2015 7
Number of Products under Development for Leukodystrophies - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Comparative Analysis by Clinical Stage Development, H1 2015 10
Comparative Analysis by Early Stage Development, H1 2015 11
Products under Development by Companies, H1 2015 12
Leukodystrophies - Pipeline by ArmaGen Technologies, Inc., H1 2015 13
Leukodystrophies - Pipeline by Fate Therapeutics, Inc., H1 2015 14
Leukodystrophies - Pipeline by GlaxoSmithKline plc, H1 2015 15
Leukodystrophies - Pipeline by Phenomenome Discoveries, Inc., H1 2015 16
Leukodystrophies - Pipeline by ReGenX Biosciences, LLC, H1 2015 17
Leukodystrophies - Pipeline by Shire Plc, H1 2015 18
Assessment by Monotherapy Products, H1 2015 19
Number of Products by Stage and Target, H1 2015 20
Number of Products by Stage and Mechanism of Action, H1 2015 21
Number of Products by Stage and Route of Administration, H1 2015 23
Number of Products by Stage and Molecule Type, H1 2015 25
Leukodystrophies Therapeutics - Recent Pipeline Updates, H1 2015 35
Leukodystrophies - Dormant Projects, H1 2015 38
Leukodystrophies - Discontinued Products, H1 2015 39

List of Figures

Number of Products under Development for Leukodystrophies, H1 2015 7
Number of Products under Development for Leukodystrophies - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Comparative Analysis by Clinical Stage Development, H1 2015 10
Assessment by Monotherapy Products, H1 2015 19
Number of Products by Stage and Top 10 Targets, H1 2015 20
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 21
Number of Products by Top 10 Routes of Administration, H1 2015 22
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 23
Number of Products by Top 10 Molecule Types, H1 2015 24
Number of Products by Stage and Top 10 Molecule Types, H1 2015 25

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Neurological Disorder Drugs Market - Europe Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Neurological Disorder Drugs Market - Europe Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

  • $ 5795
  • Industry report
  • December 2016
  • by Transparency Market Research

Europe Neurological Disorder Drugs Market: Overview This report on the neurological disorder drugs market studies the current as well as future prospects of the market in Europe. Health concern related ...

Epiomic Epidemiology Series: Muscular Dystrophies Forecast in 12 Major Markets 2017-2027

Epiomic Epidemiology Series: Muscular Dystrophies Forecast in 12 Major Markets 2017-2027

  • $ 5112
  • Industry report
  • January 2017
  • by Black Swan Analysis Ltd

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Muscular Dystrophies in 12 Major Markets The muscular dystrophies (MD) are a group of more than 30 genetic diseases characterized by ...

Epiomic Epidemiology Series: Multiple Sclerosis Forecast in 18 Major Markets 2017-2027

Epiomic Epidemiology Series: Multiple Sclerosis Forecast in 18 Major Markets 2017-2027

  • $ 5112
  • Industry report
  • January 2017
  • by Black Swan Analysis Ltd

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Multiple Sclerosis in 18 Major Markets. Multiple Sclerosis (MS) (also known as disseminated sclerosis) is a chronic, inflammatory demyelinating ...


ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.